Median Technologies announced that eyonis™ LCS, its wholly owned proprietary AI/ML-based CADe/CADx Software as a Medical Device (SaMD) for lung cancer screening, met the...
US-based Aethlon Medical has treated the first subject with its Hemopurifier investigational device in its Australian cancer trial.
Designed for subjects with solid tumours, the...
BrightHeart’s AI-based software for prenatal congenital heart defect (CHD) screening has demonstrated promise in two new studies.
The French company’s AI software received 510(k) clearance...
Risklick, a spin-off from the University of Bern, has launched its latest product, Protocol AI, for medical devices. Protocol AI is the first software of...
Pulse Biosciences has reported positive results from a first-in-human feasibility study evaluating its nanosecond pulsed field ablation (nsPFA) technology for the treatment of atrial...
STIMIT AG is enrolling patients in a U.S. Food and Drug Administration Investigational Device Exemption (IDE) clinical trial designed to evaluate its noninvasive diaphragm...
Mainstay Medical’s one-year study of its neurostimulation system for the treatment of chronic low back pain (CLBP) has demonstrated the system’s value over the...
CardioFocus published 12-month data from a study of its pulsed field ablation (PFA) system.
ECLIPSE AF, evaluated the safety and performance of the CardioFocus Centauri...
NanoVibronix has completed the first phase of a randomised control trial with UroShield, the company’s disposable ultrasound device designed to prevent catheter-associated urinary tract...
